Expanding ALS Trial Eligibility Could Benefit Patients, Therapeutic Progress | BioSpace

The majority of ALS patients are excluded from clinical trials. Experts say using biomarkers and stratifying trial populations can expand eligibility and provide additional scientific insights.

Read the full article here

Related Articles